ストックスクリーナーアプリを入手
846.27
3.42%
27.97
アフターアワーズ：
846.27
Argen X Se Adr (ARGX) 最新ニュース
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 - GlobeNewswire Inc.
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe - Zacks Investment Research
argenx reports Phase 2 FB102 celiac trial met primary endpoint - Mugglehead Investment Magazine
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - Zacks Investment Research
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? - The Motley Fool
argenx SE (1AE.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
argenx SE (ARGX.BR) Stock Price, News, Quote & History - Yahoo! Finance Canada
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline - GlobeNewswire Inc.
SGIOY Stock Price, Quote & News - Syfe
argenx at wells fargo healthcare conference: broadening beyond vyvgart By Investing.com - Investing.com India
argenx at wells fargo healthcare conference: broadening beyond vyvgart - investing.com
Argenx Se Stock Price Forecast. Should You Buy ARGX? - StockInvest.us
argenx SEADR Key Financial Ratios – Valuation, Profitability & More - Value Research
argenx to Present at Upcoming Investor Conferences - Barchart.com
BNTX Stock Price, Quote & News - Syfe
argenx (ARGX) Falters: Slides 3.37% as Bulls Defend Key $972 SupportSocial Sentiment - siam.in
argenx (ARGX) Falters: Slides 3.37% as Bulls Defend Key $972 SupportBlue Chip Entry Points - dars.gov.et
argenx SEADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Resilient Argenx stock holds near record highs after Forte Biosciences acquisition - ad-hoc-news.de
Resilient Argenx stock touches fresh all-time high after Forte Biosciences deal - ad-hoc-news.de
Argenx stock hits all-time high at 1059.86 USD By Investing.com - Investing.com South Africa
argenx Completes Acquisition of Forte Biosciences, Inc. - Barchart.com
Forte Biosciences Director David W. Gryska Sells Entire Stake Amid Merger with argenx BV - Kalkine Media
Argenx Completes Acquisition of Forte Biosciences - marketscreener.com
Why is Argen-X stock climbing today? By Investing.com - Investing.com UK
UBS upgrades argenx stock rating on Vyvgart sales outlook By Investing.com - Investing.com India
Why is Argen-X stock climbing today? - investing.com
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Argenx keeps climbing, shrugging off Deutsche Bank's reservations - marketscreener.com
Deutsche Bank Downgrades Argenx to Hold, Lifts PT - www.marketscreener.com
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Nigeria
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Australia
Deutsche Bank downgrades argenx stock to Hold on valuation - Investing.com
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? - Yahoo Finance
Resilient Argenx stock climbs after positive myositis data and fresh analyst targets - Ad-hoc-news.de
RBC Capital raises argenx stock price target on myositis data - Investing.com
Strong Argenx stock extends rally after Vyvgart trial win and analyst target hikes. - Ad-hoc-news.de
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Sahm
Citizens raises argenx stock price target to $1,200 on trial results - Investing.com
argenx (ARGX) Latest Price Review: Adds 0.52% to Close at $992.99; Key Levels: the Supplied Trading Band Runs From $943.34 to $1,042.64 for the Current SessionMerger Arbitrage - dars.gov.et
Argenx's Positive Vyvgart Data in Autoimmune Indication Supports Growth and FB102 Broadens Portfolio - Morningstar
Resilient Argenx stock jumps after positive Vyvgart Phase 3 data - Ad-hoc-news.de
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com Australia
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Benzinga
ARGX Stock Price, Quote & Chart - ChartMill
European ADRs Started The Week Slightly Higher In US Trading - Finimize
6.43%
2.20%
大文字化:
|
ボリューム (24 時間):